Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ALT
Altimmune, Inc. (ALT) EV/Sales
As of 12 October 2026, Altimmune, Inc. (ALT) trades at a EV/Sales of 3,985×. Over the past ten years it has ranged from −8,907× (January 2023) to 21,654× (June 2025); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 9.6× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1,718× | (90.97%) |
| FY2024 | 19,024× | 2,133.92% |
| FY2023 | 852× | — |
| FY2022 | −8,079× | — |
| FY2021 | 42.9× | 368.81% |
| FY2020 | 9.1× | — |
| FY2019 | −1.9× | — |
| FY2018 | −2.7× | — |
| FY2017 | 1.3× | — |
| FY2016 | −0.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1,718× | (75.62%) |
| Sep 2025 | 7,045× | (3.93%) |
| Jun 2025 | 7,334× | (35.77%) |
| Mar 2025 | 11,417× | (39.98%) |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ARVN Arvinas, Inc. compare | −0.3× |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | 27.9× |
| OCS Oculis Holding AG compare | 133× |
| PROK ProKidney Corp. compare | 159× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | 759× |
| ALT Altimmune, Inc. | 3,985× |
| Biotechnology industry median | 9.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)